Literature DB >> 27458238

Releasing the brakes to fight cancer: The recent discovery of checkpoints has boosted the field of cancer immunotherapy.

Katrin Weigmann1.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 27458238      PMCID: PMC5007568          DOI: 10.15252/embr.201643038

Source DB:  PubMed          Journal:  EMBO Rep        ISSN: 1469-221X            Impact factor:   8.807


× No keyword cloud information.
  6 in total

1.  Coley toxins immunotherapy: a retrospective review.

Authors:  M A Richardson; T Ramirez; N C Russell; L A Moye
Journal:  Altern Ther Health Med       Date:  1999-05       Impact factor: 1.305

2.  Checkpoints.

Authors:  James P Allison
Journal:  Cell       Date:  2015-09-10       Impact factor: 41.582

3.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

4.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

5.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P van der Bruggen; C Traversari; P Chomez; C Lurquin; E De Plaen; B Van den Eynde; A Knuth; T Boon
Journal:  Science       Date:  1991-12-13       Impact factor: 47.728

6.  Enhancement of antitumor immunity by CTLA-4 blockade.

Authors:  D R Leach; M F Krummel; J P Allison
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

  6 in total
  2 in total

1.  Robust immune response stimulated by in situ injection of CpG/αOX40/cGAMP in αPD-1-resistant malignancy.

Authors:  Luya Cai; Xuedan Du; Cheng Zhang; Shanshan Yu; Lixiao Liu; Jinduo Zhao; Ye Zhao; Chunhong Zhang; Jinting Wu; Bin Wang; Yingyu Chen; Xiaoping Su; Xiaojian Yan; Wenfeng Li
Journal:  Cancer Immunol Immunother       Date:  2021-11-03       Impact factor: 6.630

2.  Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression.

Authors:  Linlin Shi; Jianyong Sheng; Mengli Wang; Han Luo; Jun Zhu; Bixiang Zhang; Zhi Liu; Xiangliang Yang
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.